Mivi Neuroscience is an Eden Prairie, Minn.-based medical device company focused on improving clinical outcomes for ischemic stroke patients. It develops and commercializes neurointerventional devices, including its two flagship products, the Q™ Aspiration System and the DAISe™ Thrombectomy System. Its product portfolio is designed to reduce complications, shorten procedure times and expand treatment to more patients. The company closed a $35M Series B in new money plus the conversion of previously issued convertible notes to fund clinical trials and subsequent commercialization. Proceeds will also support expansion of commercial operations outside the United States and the development of several innovative devices to support and enhance its products. The company is led by CEO Bob Colloton. MIVI Neuroscience develops medical devices for neuro-interventional procedures, with a product portfolio designed to improve outcomes and shorten procedure times. Its tools aim to enable easier access to smaller, difficult-to-treat cerebral vessels and potentially expand treatment to more patients. The company’s devices are positioned for endovascular stroke therapy, a field that has seen significant global growth since pivotal clinical trials in 2015–2016. MIVI aims to make treatment available to more patients by providing access to smaller vessels in the brain. The article reports that Concord Health Partners has completed an investment in MIVI, reflecting investor interest in its proprietary technologies that may lower costs and enhance the value of care.

Total raised

$35M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2021